Viriom Announces New Director Appointment

SAN DIEGO, Dec. 6, 2017  /PRNewswire/ -- Viriom Inc. is pleased to announce the appointment of Augustine Lawlor as Director of Viriom. Mr. Lawlor brings to Viriom his extensive operating experience in strategic business development, finance, management of mergers and acquisitions, as well as general management in the biotechnology industry.

Mr. Lawlor is the Managing Partner of HealthCare Ventures LLC, where he has worked for over 17 years, and a board member of numerous life science companies. Before joining HealthCare Ventures, Mr. Lawlor served as Vice President of Corporate Development & Chief Financial Officer, and later as Chief Operating Officer, at LeukoSite, Inc. Prior to that, Mr. Lawlor was the Chief Financial Officer and Vice President of Corporate Development at Alpha-Beta Technology, and held similar positions at BioSurface Technology and Armstrong Pharmaceuticals, Inc. Earlier, he was working for KPMG as a management consultant. Mr. Lawlor received his Master's degree in Public and Private Management from Yale University.

"Mr. Lawlor's expertise in the intricate workings of the biotechnology industry and his knowledge of the most efficient results-driven business development strategies will help accelerate Viriom's efforts in developing a truly global antiviral platform," said Nikolay Savchuk, PhD, Chairman of the Viriom Board. "We are excited to work together on offering novel and affordable therapies against life-threatening infections including HIV and hepatitis B."

"The main reason why millions of people still live with HIV and HBV, and thousands keep getting infected every day, is the unaffordability of modern treatments," commented Augustine Lawlor.  "Viriom offers a solution: antiviral treatments that are not only effective, but also affordable, and can be used for both treatment and prophylaxis. Viriom's cost-effective approach to drug development at scale can bring the much-needed solution to HIV and HBV problems around the globe, and I am delighted to be a part of Viriom's team and to contribute to advancing its novel therapies."

About Viriom

Viriom Inc. is a late-stage biotech company developing, manufacturing and distributing novel and affordable therapies against life-threatening infections such as HIV and HBV. Viriom holds exclusive worldwide rights from F. Hoffmann-La Roche for VM1500, which it is presently developing as an oral AIDS treatment (Elsulfavirine) for active HIV infections; and as innovative longer-acting formulations of Elsulfavirine for PrEP and PEP in high-risk patient populations. Viriom is also developing a proprietary therapeutic for chronic HBV infections. Viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of HIV and chronic HBV infections in both developing and developed countries. For more information, please visit

Viriom will Present Latest Preclinical Data on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development at the 16th European AIDS Conference in Milano

SAN DIEGO, CA, October 3d, 2017 -- Viriom Inc. announced today that it will be presenting “Preclinical Development of Elsulfavirine/VM1500A Long Acting Injectable Formulations" at the 16th European AIDS Conference in Milano, Italy. The study evaluates new options for treatment and prevention of AIDS, especially for patients with resistant HIV strains, that would allow for infrequent dosing, thus facilitating patients’ adherence and likely improving long-term treatment outcomes. Viriom invites interested researchers and physicians to the poster viewing session on Wednesday, October 25, 15:00 to 17:00. The study results will be presented by Dr. Kan and Dr. Bichko, CSO of Viriom.

In addition, Viriom is participating in IDweek2017 from October 4th to October 8th in San Diego, CA, and invites partners with breakthrough HIV therapies and prophylactics to meet at the convention or visit Viriom offices at 6605 Nancy Ridge Drive, San Diego CA 92121.  

Viriom also invites interested researchers and physicians to attend the launch symposium of Elpida® - “First in XXI Century. Innovations in HIV treatment in Russia” at 12-13.30 pm on October 5th within the framework of the 2nd St. Petersburg Forum on HIV/AIDS infection “Modern Aspects of Prophylaxis, Diagnostics and Treatment”, where Dr. Hammond, Dr. Petrovich, Dr. Kravchenko, Dr. Efimov and Dr. Nagimova will be presenting at the panel discussion.

The results of an earlier study, “Red Blood Cells are a Natural Slow Release Depot for Elsulfavirine/VM1500A HIV NNRTI”, were reported by Dr. Bichko at the 20th European Society for Clinical Virology (ESCV) annual meeting during the “HIV and Other Retroviruses” oral session on September 14 in Stresa, Italy. The study explained VM1500A beneficially long plasma elimination half-life after oral administration of Elsulfavirine.

“We are very pleased with the latest clinical results and most importantly with our first launch activities,” commented Nikolay Savchuk, Chairman of the Board of Viriom. “Elsulfavirine has shown its virologic and immunologic efficacy in various formulations, combinations, and routs of administration, demonstrating its potential as a unique multidimensional therapeutic alternative for unmet needs in safe, tolerable and long acting regiments for HIV treatment, importantly including patients with drug-resistant HIV mutations or high viral load before treatment.”

About Viriom

Viriom focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to antiviral treatments and prophylaxis. Viriom’s broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV/AIDS and other highly communicable diseases. Viriom’s most advanced drug is Elpida/Elsulfavirine, a once-daily 20 mg oral prodrug of VM-1500A, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI). Development is underway for once-weekly oral and longer-acting parenteral formulations of Elpida/Elsulfavirine, combination and formulations with VM-2500 proprietary pro-drug nucleoside inhibitor and other drugs. Learn more at

Viriom Obtains First Market Approval of Elsulfavirine (Elpida®) for Treatment of HIV-1 Infection in Russia

- Viriom's 20mg Daily Elsulfavirine (Elpida®)-based Regimen Demonstrated High Efficacy in High and Low HIV Titer Patients with Significantly Improved Safety Compared with 600mg Efavirenz-based Regimens -

Viriom to Present Results of Pre-Clinical Pharmacokinetic Studies with Elsulfavirine and VM1500A Long Acting Injectable Formulations at the International AIDS Society (IAS) Conference 2017

SAN DIEGO, CA, May 22, 2017 -- Viriom Inc. today announced that the data from pre-clinical studies of Elsulfavirine/VM1500A Long Acting Injectable Formulations will be presented at the 9th IAS (International AIDS Society) Conference on HIV Science (IAS 2017), to be held July 23-26 in Paris, France.

Viriom Announces Interim Results from Phase 3 Clinical Trials with Elsulfavirine Were Presented at Largest Events on HIV/AIDS in Moscow

April 7, 2016 – Viriom, a member of the ChemRar High-Tech Center, announced today that interim results from Phase 3 clinical trials with the drug Elpida®, a new highly selective non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV/AIDS, have been presented to the Russian and international communities at notable events on HIV infection held in Moscow recently.

Viriom, Inc. Announces the Publication of Results from an Efficacy and Safety Study with Elsulfavirine in the Journal “National Scientific Society of Infectious Disease Specialists”

December 14, 2015 – Viriom, a member of the ChemRar High-Tech Center, announced today that the article, "The efficacy and safety of a new Russian HIV non-nucleoside reverse transcriptase inhibitor (Elpida®; VM-1500, Elpivirine; as a component of an antiretroviral therapy regimen" was published in the journal, "Epidemiology and Infectious Diseases. Present-day Questions" № 5, 2015. ( This well-regarded medical and scientific journal is a publication of the National Scientific Society of Infectious Disease Specialists.

Viriom Successfully Completes Government Contract for Development of Innovative HIV Treatment

Viriom, a member of the ChemRar High-Tech Center, successfully completed the government contract with the Ministry of Industry and Trade of the Russian Federation for developing an innovative drug, a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus, for the treatment of HIV/AIDS and conducting its preclinical and clinical studies.

Viriom Reports Clinical Efficacy Data for VM-1500, a New HIV NNRTI

Moscow, Russia, October 8, 2013 - Dr. Vadim Bichko, Chief Scientific Officer of Viriom, presented positive interim results of Phase Ib/IIa study with VM-1500, a new HIV NNRTI (non-nucleoside reverse transcriptase inhibitor), at the 15th Annual International Meeting of the Institute of Human Virology (held September 8-11, 2013, in Moscow, Russia).

In part I of the trial, a placebo-controlled randomized study of the safety and pharmacokinetics of VM-1500 in healthy volunteers, 12 healthy volunteers were randomized to receive a single oral dose of 20 or 40 mg VM-1500 or placebo. VM-1500 was well-tolerated; no significant adverse events (SAE) were reported. 

In part II of the study, the safety, tolerability, and antiviral activity of VM-1500 were assessed in HIV-1 infected patients. A total of 16 HIV-1 infected, treatment-naive subjects were randomized to receive 20 or 40 mg VM-1500 or placebo QD for 7 days. The 20 mg dose was safe and well-tolerated, and no SAEs were reported during VM1500 administration. Pharmacokinetic analyses confirmed high drug exposure and long half-elimination time, supporting once-daily dosing. All 7 HIV-1 infected subjects from the 20 mg cohort achieved strong virologic response with a median HIV RNA reduction of 1.73 log10 IU/ml after 7 days of treatment.

Clinical studies conducted to date demonstrate that VM-1500 is a well-tolerated, safe, and effective HIV NNRTI. An international Phase II study is scheduled to begin in Q1 of 2014.

In 2009, Viriom Ltd. was the first company in Russia to complete a technology transfer licensing arrangement with the Swiss company F. Hoffmann-La Roche, and obtained the rights to develop and manufacture an innovative candidate for treating HIV/AIDS in Russia and the CIS. Viriom completed a program of pre-clinical trials, and is currently conducting a number of clinical trials in Russia and internationally.

Andrey Ivaschenko, Chairman of ChemRar High-Tech Center commented, “This was the first transfer deal involving a big international pharma, where development has been assigned to a Russian company to take [a drug] all the way to manufacturing. Therefore, it is very important that the initial clinical trials support the expectations of the partners, and there is now a significant likelihood that the best drug in this class in the world will be created in Russia.” 

Viriom’s development of VM-1500 was among the first projects supported by the Russian Ministry of Industry and Trade under the auspices of the federal targeted program “Development of the Pharmaceutical and Medical Industry in the Russian Federation for the Period of 2020 and beyond”.

About Viriom

Viriom Ltd. is a ChemRar company involved in developing innovative antiviral drugs and combinations, treatment methods, and diagnostics. Viriom conducts scientific research in Russia, using the experience and knowledge of Russian scientists, and abroad within the framework of a broad international partnership. The Viriom project was approved by the Russian President’s Commission on Modernization. The ChemDiv Research Institute is Viriom's major partner in pre-clinical and clinical research. Clinical studies within Russia are conducted at regional centers and on the campus of the Moscow City Center for Preventing and Treating AIDS. Among Viriom’s international partners are Hoffmann-La Roche, Fox Chase Cancer Center (Philadelphia, PA), the Scripps Research Institute (San Diego, CA), the Moscow Physics and Technology Institute, and the M.P. Chumakov Institute for Poliomyelitis and Viral Encephalitis (Moscow, Russia).

International Virology Week Conference

The applied research conference “International Virology Week” is a global initiative where leading Russian and international scientists meet to discuss the most pressing issues in the development of new antiviral drugs, as well as optimal techniques to diagnose and prevent various viral infections. This year, the conference attracted more than 100 leading virologists from Western Europe and the US.

One of the key themes of the global conference was the fight against HIV infection. According to data from WHO and UNICEF, there are currently around 34 million people infected with HIV; and this number increases annually by around half a million.* Thanks to the latest methods of treatment, it has been possible to reduce mortality significantly; and to increase the length and quality of life of infected patients. But the main problem for world scientists remains the development of a drug that can completely destroy the virus. According to Alexei Mazus, head of the Moscow City Center for Preventing and Treating AIDS, Russia has expertise in working to resolve this issue. This conference was supported by the Moscow Department of Public Health, the Moscow City Center for Preventing and Treating AIDS, the Institute for Human Virology, and the Global Virological Network.

*Global HIV/AIDS Response: epidemic update and health sector progress towards Universal Access: progress Report 2011. Geneva, World Health Organization, 2011

Media Contact:

Elena Surina

Viriom Presented the Results of Efficacy Studies of its Innovative HIV Treatment at Moscow International Virology Week

Dr. Vadim Bychko, Research Director at Viriom, announced the results of efficacy studies of Viriom's innovative candidate for the treatment of HIV/AIDS at the "Moscow International Virology Week" conference. Viriom's innovative drug VM-1500 demonstrated its unique pharmacokinetic characteristics in the clinical studies, exhibiting high efficiency and resistance to HIV that surpass those of other drugs in its class.